Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer-Reference-Cited by-同舟云学术

Current issues with luminal subtype classification in terms of prediction of benefit from endocrine therapy in early breast cancer

Published:2018-05-28 Issue:4 Volume:73 Page:545-558
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Alfarsi Lutfi¹,Johnston Simon¹,Liu Dong-Xu²,Rakha Emad¹³,Green Andrew R¹^ORCID

Affiliation:

1. Nottingham Breast Cancer Research Centre; Division of Cancer and Stem Cells; School of Medicine; University of Nottingham; Nottingham City Hospital; Nottingham UK

2. The Centre for Biomedical and Chemical Sciences; School of Science; Faculty of Health and Environmental Sciences; Auckland University of Technology; Auckland New Zealand

3. Cellular Pathology; Nottingham University Hospitals NHS Trust; Nottingham UK

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/his.13523/fullpdf

Reference90 articles.

1. Tamoxifen resistance: emerging molecular targets;Rondón-Lagos;Int. J. Mol. Sci.,2016

2. Time to stop progesterone receptor testing in breast cancer management;Olivotto;J. Clin. Oncol.,2004

3. Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study;Purdie;Br. J. Cancer,2014

4. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer;Prat;J. Clin. Oncol.,2013

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting hormone receptor status in invasive breast cancer through radiomics analysis of long-axis and short-axis ultrasound planes;Scientific Reports;2024-07-30

2. p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer;F1000Research;2022-11-30

3. Delving into the Heterogeneity of Different Breast Cancer Subtypes and the Prognostic Models Utilizing scRNA-Seq and Bulk RNA-Seq;International Journal of Molecular Sciences;2022-09-01

4. p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer;F1000Research;2022-03-18

5. Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer;Bioscience Reports;2022-01